JPRN-UMIN000007726已完成未知
S-1/CDDP and Lentinan for Advanced Stomach cancer - SPLASH study
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Serious drug hypersesitivity 2)Active infection 3)Clitical condition of heart disease 4)Serious coexisting illness diabetes mellitus,uncontrolled or controlled with insulin,liver cirrhosis,renal disfunction,severe pulmonary dysfunction,bowel dysfunction,history of myocardial infarction 5)Massive hydrothorax or ascites 6)Multiple bone metastases 7)Brain metastasis 8)Active bleeding of digestive tract 9)Diarrhea 10)Severe mental disorders 11)Have other cancers than gastric cancer 12)Pregnant or nursing 13)Pregnant or nursing 14)Not suitable for participating in the study for any other reason
研究者
相似试验
已完成
2 期
PhaseII study of S-1/CDDP therapy for Gastric Cancer that Recurs After Adjuvant Chemotherapy with S-1Gastric CancerJPRN-UMIN000004303Kyushu Study group of Clinical Cancer44
未知
不适用
S-1 as second line for non-small cell lung cancer with preexisting interstitial pneumonia: phase II study.non-small cell lung cancerJPRN-UMIN000022165Hamamatsu University School of Medicine28
招募中
2 期
The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach CancerGastric CancerNCT05000554The First Hospital of Jilin University30
已完成
2 期
Phase II study of S-1 for non-small lung cancer after failure of two or three prior chemotherapy regimenson Small Cell Lung Cancer (NSCLC)JPRN-UMIN000003986ational Hospital Organization Asahikawa Medical Cencer40
Unknown
2 期
PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical TrialHepatocellular CarcinomaNCT04814043Sun Yat-sen University57